Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib and Penpulimab in Advanced Head, Neck, and Chest Cancers
NCT04203719Phase 2Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- May 2020
- Primary completion
- Dec 2020
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of penpulimab and anlotinib in head and neck squamous cell carcinoma (HNSCC), head and neck cancer (HNC), undifferentiated thyroid cancer (ATC) and 4 more, sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoint: Overall Response Rate up to 96 weeks. Status: unknown.
02
Drugs
penpulimabanlotinib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)head and neck cancer (HNC)undifferentiated thyroid cancer (ATC)small cell lung cancer (SCLC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04203719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04203719.